Show simple item record

dc.contributor.authorPunta, M
dc.contributor.authorJennings, VA
dc.contributor.authorMelcher, AA
dc.contributor.authorLise, S
dc.date.accessioned2021-03-12T12:17:45Z
dc.date.available2021-03-12T12:17:45Z
dc.identifier.citationFrontiers in immunology, 2020, 11 pp. 524968 - ?
dc.identifier.issn1664-3224
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4415
dc.identifier.eissn1664-3224
dc.identifier.eissn1664-3224en_US
dc.identifier.doi10.3389/fimmu.2020.524968
dc.identifier.doi10.3389/fimmu.2020.524968en_US
dc.description.abstractCancer somatic mutations have been identified as a source of antigens that can be targeted by cancer immunotherapy. In this work, expanding on previous studies, we analyze the HLA-presentation properties of mutations that are known to drive resistance to cancer targeted-therapies. We survey a large dataset of mutations that confer resistance to different drugs and occur in numerous genes and tumor types. We show that a significant number of them are predicted <i>in silico</i> to be potentially immunogenic across a large proportion of the human population. Further, by analyzing a cohort of patients carrying a small subset of these resistance mutations, we provide evidence that what is observed in the general population may be indicative of the mutations' immunogenic potential in resistant patients. Two of the mutations in our dataset had previously been experimentally validated by others and it was confirmed that some of their associated neopeptides elicit T-cell responses <i>in vitro</i>. The identification of potent cancer-specific antigens can be instrumental for developing more effective immunotherapies. In this work, we propose a novel list of drug-resistance mutations, several of which are recurrent, that could be of particular interest in the context of off-the-shelf precision immunotherapies such as therapeutic cancer vaccines.
dc.formatElectronic-eCollection
dc.format.extent524968 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleThe Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An <i>In Silico</i> Study.
dc.typeJournal Article
dcterms.dateAccepted2020-09-14
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3389/fimmu.2020.524968
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFrontiers in immunology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL)
pubs.publication-statusPublished
pubs.volume11en_US
pubs.embargo.termsNot known
icr.researchteamTranslational Immunotherapy
icr.researchteamTranslational Immunotherapyen_US
dc.contributor.icrauthorMelcher, Alanen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/